Overview

Study of CBX-12 in Subjects With Advanced or Metastatic Refractory Solid Tumors

Status:
Recruiting
Trial end date:
2024-04-01
Target enrollment:
Participant gender:
Summary
This is a first-in-human, Phase 1/2 open-label, multicenter, dose-escalation, safety, pharmacokinetics (PK), and biomarker study of CBX-12 in subjects with advanced or metastatic refractory solid tumors.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Cybrexa Therapeutics